We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Investigational Drug Fails As Standalone Mesothelioma Treatment, AstraZeneca Says

(February 29, 2016, 10:38 AM EST) -- LONDON — The investigational drug Tremelimumab does not improve overall survival rates of mesothelioma patients when used alone, AstraZeneca announced Feb. 29.

In its release, AstraZeneca said Tremelimumab remains a key component in combination treatments for various types of tumors.

Tremelimumab is currently being studied in combination with another AstraZeneca drug, Durvalumab, as a treatment for numerous tumors, including non-small cell lung cancer, squamous cell carcinoma of the head and neck, bladder, pancreatic, gastric and liver cancers, the company said.

Tremelimumab is a selective antibody drug...
To view the full article, register now.